Share
Wednesday, May 5, 2021 Bob Li says, For America to keep growing stronger, it is essential that we stand in solidarity and speak out against all forms of racism and discrimination.
In 2014, Bob Li was a medical oncology clinical research fellow at Royal North Shore Hospital in Sydney, Australia, one of the best in the country. His career was just budding. He and his wife had friends and family members nearby. Life was comfortable.
But Dr. Li saw opportunity in America. He applied for a fellowship halfway across the world at Memorial Sloan Kettering Cancer Center in New York City.
“In the oncology world, MSK is like Mount Everest, ” he says.
中油攜手林園區公所淨灘守護海洋向海致敬 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
中油攜手林園區公所 動員淨灘守護海洋向海致敬 sina.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.tw Daily Mail and Mail on Sunday newspapers.
Seksan Mongkhonkhamsao/Getty Images
Over the course of the last 15 years, the discovery that some lung cancers are driven by gene mutations that can be targeted with drugs has dramatically increased survival time for many patients. However, one identified mutation, to the KRAS gene, has eluded effective drugs.
Data from a phase 2 trial presented at the conference showed that, of 126 patients with non-small-cell lung cancer and a KRAS mutation treated with the experimental cancer drug sotorasib, 37.1 percent responded.
The average progression-free survival for all patients in the trial (the length of time in which the tumor did not grow) was 6.8 months. For patients who responded to the drug, the duration of the response lasted on average for 10 months.
Fewer than or equal to three prior lines of therapy.
Patients with untreated active brain metastases were excluded.
Enrolled patients were followed for a median period of 12.2 months. An independent blinded central review of the patients found that 124 patients had at least one measurable lesion at baseline and were evaluated for efficacy. Of these, 46 patients experienced a confirmed response (three complete responses and 43 partial responses), resulting in an objective response rate of 37.1% (95% Cl: 28.6–46.2). The median time to objective response was 1.4 months, the median duration of response was 10 months (95% CI: 6.9-11.1), and 43% of responders remained on treatment without progression. The disease control rate was 80.6% (95% Cl: 72.6–87.2).